U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT07572656) titled 'Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia' on May 01.
Brief Summary: Due to limited data regarding preeclampsia from the local population, the debate is still ongoing in the study setting. Hence, the current study was planned to compare the efficacy of labetalol and hydralazine for the treatment of hypertension in patients with severe preeclampsia.
Study Start Date: May 01, 2024
Study Type: INTERVENTIONAL
Condition:
Preeclampsia
Intervention:
DRUG: Labetalol
Patients were given a 20 mg bolus dose of labetalol in 2 minutes, and blood pressure was checked after 20 minutes; if not effec...